United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

After three years in the making, Huntsville International is taking strides in improving storage for aircraft.

These companies valuations have fluctuated since - Exelixis' is now valued at $10.65bn, Genmab, $13.7bn, Alnylam, $32.4bn, BioMarin, $11.7bn, and United Therapeutics, $16.1bn, while Sarepta's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...